No Data
No Data
Alumis Presents 28-Week Data From Open Label Extension Period Of Phase 2 STRIDE Trial Of ESK-001; Says '28-week Data Show ESK-001 Was Generally Well Tolerated and Most Patients Treated With the Top Dose of 40 Mg Twice Daily Achieved PASI 75'
Stride Publishes Study Revealing Financial Challenges Faced by Millions of Independent Workers
Beanstalk Benefits Launches New Partnerships, Extends Platform to Include Part-Time and Contract Employees
Express News | Medcerts Launches Certified Cing Assistant (CNA) Elearning Program Benefiting Medical Providers, Patients and Aspiring Healthcare Professionals
Barrington Research Maintains Outperform on Stride, Maintains $90 Price Target
Stride Analyst Ratings